‘Dressed for success’ C-type lectin receptors for the delivery of glyco-vaccines to dendritic cells

Current strategies in immunotherapy for the treatment of tumors or autoimmunity focus on direct in vivo targeting of antigens to dendritic cells (DC), as these cells are the key regulators of immune responses. Multiple DC subsets can be distinguished in both humans and mice, based on phenotype and l...

Full description

Saved in:
Bibliographic Details
Published inCurrent opinion in immunology Vol. 23; no. 1; pp. 131 - 137
Main Authors Unger, Wendy WJ, van Kooyk, Yvette
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.02.2011
Subjects
Allergy and Immunology
Animals
Antigens - immunology
Carbohydrates - immunology
Dendritic Cells - immunology
Humans
Immune Tolerance
Lectins, C-Type - immunology
Vaccines - immunology
Online AccessGet full text

Cover

More Information
Summary:Current strategies in immunotherapy for the treatment of tumors or autoimmunity focus on direct in vivo targeting of antigens to dendritic cells (DC), as these cells are the key regulators of immune responses. Multiple DC subsets can be distinguished in both humans and mice, based on phenotype and location. Moreover, recent data show that these subsets have distinct functions. All these features have implications for the design of DC-targeting vaccines. In this review we integrate recent knowledge on the different DC subsets in human and mice and how DC-expressed C-type lectin receptors (CLR) can be exploited for the induction of either antigen-specific immunity or tolerance.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ObjectType-Feature-1
ISSN:0952-7915
1879-0372
DOI:10.1016/j.coi.2010.11.011